Sp02
Brentuximab Vedotin versus checkpoint inhibitors: Which one? When? Why should be preferred?
Murat Özbalak
Ağrı Research and Training Hospital, Division of Hematology, Ağrı/TURKEY
Lido
1560
Vezesque se leu este artigo
689
Total PDF
871
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 7 | 46 | 13 | 59 |
| 2025 6 | 44 | 26 | 70 |
| 2025 5 | 56 | 11 | 67 |
| 2025 4 | 45 | 15 | 60 |
| 2025 3 | 49 | 17 | 66 |
| 2025 2 | 48 | 27 | 75 |
| 2025 1 | 27 | 16 | 43 |
| 2024 12 | 28 | 23 | 51 |
| 2024 11 | 25 | 21 | 46 |
| 2024 10 | 38 | 20 | 58 |
| 2024 9 | 37 | 24 | 61 |
| 2024 8 | 39 | 20 | 59 |
| 2024 7 | 41 | 26 | 67 |
| 2024 6 | 32 | 29 | 61 |
| 2024 5 | 38 | 22 | 60 |
| 2024 4 | 33 | 16 | 49 |
| 2024 3 | 22 | 22 | 44 |
| 2024 2 | 15 | 22 | 37 |
| 2024 1 | 13 | 22 | 35 |
| 2023 12 | 17 | 17 | 34 |
| 2023 11 | 20 | 28 | 48 |
| 2023 10 | 12 | 26 | 38 |
| 2023 9 | 15 | 30 | 45 |
| 2023 8 | 10 | 12 | 22 |
| 2023 7 | 15 | 21 | 36 |
| 2023 6 | 20 | 15 | 35 |
| 2023 5 | 15 | 21 | 36 |
| 2023 4 | 11 | 5 | 16 |
| 2023 3 | 9 | 18 | 27 |
| 2023 2 | 7 | 18 | 25 |
| 2023 1 | 12 | 17 | 29 |
| 2022 12 | 13 | 27 | 40 |
| 2022 11 | 10 | 15 | 25 |
| 2022 10 | 9 | 27 | 36 |
Mostrar tudo
